Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Acquisitions (2016 - 2018)

Integra Lifesciences Holdings (IART) has disclosed Acquisitions for 10 consecutive years, with -$53.4 million as the latest value for Q4 2018.

  • Quarterly Acquisitions fell 105.25% to -$53.4 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$53.4 million through Sep 2023, changed N/A year-over-year, with the annual reading at $30.5 million for FY2019, 214.25% up from the prior year.
  • Acquisitions hit -$53.4 million in Q4 2018 for Integra Lifesciences Holdings, down from $21.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $1.0 billion in Q4 2017 to a low of -$53.4 million in Q4 2018.
  • Historically, Acquisitions has averaged $124.3 million across 5 years, with a median of $5.7 million in 2018.
  • Biggest five-year swings in Acquisitions: skyrocketed 451830.67% in 2017 and later plummeted 105.25% in 2018.
  • Year by year, Acquisitions stood at $85.9 million in 2014, then soared by 282.78% to $328.9 million in 2015, then plummeted by 100.07% to -$225000.0 in 2016, then surged by 451830.67% to $1.0 billion in 2017, then tumbled by 105.25% to -$53.4 million in 2018.
  • Business Quant data shows Acquisitions for IART at -$53.4 million in Q4 2018, $21.0 million in Q2 2018, and $5.7 million in Q1 2018.